ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...
The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. | The emergence of ...
Verastem, Inc. shifts focus to VS-7375 for KRAS G12D tumors after ending RAMP-203. Click to learn about VSTM's key catalysts ...
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, ...
Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and ...
Several reports have noted that individuals with NSCLC whose tumors are documented to contain a mutation in the EGFR receptor have a substantially greater chance of responding to small-molecule ...
The HER2-specific tyrosine kinase inhibitor zongertinib was well tolerated and demonstrated promising efficacy in patients with HER2 mutation-positive non-small cell lung cancer, meeting the primary ...
SAN DIEGO--(BUSINESS WIRE)--Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced findings from a study using the Cellworks Platform ...
TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung ...
A year ago, ASCO released a clinical practice guideline on systemic therapy for patients with stage IV non-small cell lung cancer (NSCLC) without driver alterations. Part two has now been released, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback